30 closest matches · ranked by relevance
Lung Cancer, Non-Small Cell · Metastatic Squamous Cell Carcinoma · Metastatic Non-Squamous Cell Carcinoma
Primary: Safety/Tolerability of ADXS-503 Monotherapy in Part A and ADXS-503 With Pembrolizumab in Part B: Graded Per Comment Terminology Criteria for Adverse Events (CTCAE)…
Lung Cancer
Primary: Number of Participants With a Response — 4 Participants — p=0.161
Squamous Non-small Cell Lung Cancer
Primary: Time on Treatment With Afatinib or Chemotherapy During Second Line (2L) Treatment — 7.3; 4.2 months
Non Small Cell Lung Cancer
Primary: 3-Year Overall Survival Rate — 45 percentage of participants
Non-small-cell Lung Cancer
Primary: Estimated Overall Survival — 0.54; 0.56; 0.54; 0.56 proportion of participants — p=0.73
Lung Cancer
Primary: Objective Response Rate (ORR) — 7.69 percentage of participants
Carcinoma, Non-Small-Cell Lung (NSCLC)
Primary: Percentage of Participants With Objective Response (OR) — 39.5 Percentage of participants
Non Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) During the Induction and Maintenance Therapy Periods — 5.6 months
Non-Small Cell Lung Cancer
Primary: Percentage of Participants With Major Pathologic Response (MPR) — 20.3 percentage of participants — p=<.0001
Non-Small Cell Lung Cancer
Primary: Number of Participants With High Grade (Grade 3, 4 and 5) Treatment Related Select Adverse Events — 1; 7; 0; 1 Participants
Squamous Cell Lung Carcinoma
Primary: Objective Response Rate (ORR) — 0 Participants
Non-Small Cell Lung Cancer
Primary: The Feasibility of Post-Surgery Chemotherapy — 38; 27; 18; 6 participants
Non-small-cell Lung Cancer
Primary: Response Assessment by Study Stratum - Per Investigator Assessment — 0; 6; 3; 7 Participants
Lung Cancer · Untreated Stage IV or Recurrent Squamous Cell Lung Cancers
Primary: Overall Response Rate — 18; 1; 5; 12 Participants
Patients With Stage IV or Recurrent Adenocarcinoma of the Lung
Primary: Overall Response Rate — 13.5 percentage of participants
NSCLC Non-small Cell Lung Cancer
Primary: Event-free Survival (EFS) Rate — 73.4 percentage of participants
Carcinoma, Non-Small-Cell Lung
Primary: Disease Control Rate at 12 Weeks — 6; 6 participants
Non Small Cell Lung Cancer
Primary: Progression Free Survival — 77.1 percentage of participants
Carcinoma, Non-Small-Cell Lung
Primary: Objective Response Rate (ORR) — 16.7; 8.3 Percentage of Participants
Non-Small-Cell Lung Cancer
Primary: Median Time to Progression (TTP) — 6.11 months
Lung Cancer
Primary: Progression Free Survival (PFS) — 4.8 months
Lung Cancer
Primary: Progression-Free Survival — 4.1; 3.9 months
Adenocarcinoma of the Lung
Primary: Progression-free Survival (PFS) — 5.8; 4.7; 5.9; 4.7 Months — p=0.3519
Carcinoma, Non-Small Cell Lung
Primary: Progression-Free Survival (PFS) — 8.0; 8.1; 7.1 months — p=0.3037
Lung Neoplasms · Carcinoma, Non-small Cell Lung
Primary: Percentage of Participants With Objective Response (OR) — 9.4 Percentage of participants
Lung Cancer
Primary: PERCIST Partial Metabolic Response — 6 participants
Carcinoma, Large Cell · Neuroendocrine Tumors
Primary: Percentage of Participants Progression-free — 49.0 Percentage of participants
Non-Small Cell Lung Cancer Stage IV
Primary: Progression Free Survival (PFS) — 2.53; 4.21 months — p=0.0068
Advanced Non-small Cell Lung Cancer
Primary: Best Overall Response (BOR) — 2; 2; 9; 1 Participants
Lung Cancer · Non Small Cell Lung Carcinoma · Hypermethylation
Primary: Percentage of Patients Showing a Presence of Methylated Tumor Suppressor Genes in Their Tumor Tissue and/or Serum Achieving Partial or Complete Response to Protocol…